PDCD1 and Kaposi's sarcoma: In a phase II clinical trial studying the PD-1 inhibitor pembrolizumab for treating classic KS, 2 patients achieved complete remission, 10 had partial remissions, and 5 had stable disease after 204 months of follow-up.